Long-term therapeutic efficacy of lamivudine compared with interferon-α in children with chronic hepatitis B: The younger the better

Journal of Pediatric Gastroenterology and Nutrition

Volumn 44, Issue 1, 2007, Pages 92-98

  Choe, Byung Ho ^a,b   Lee, Ji Hye ^a   Jang, You Cheol ^a   Jang, Chang Hwan ^a   Oh, Ki Won ^a   Kwon, Soonhak ^a   Hyun, Myung Chul ^a   Ko, Cheol Woo ^a   Lee, Kun Soo ^a   Lee, Won Kee ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

Author keywords

Children; Chronic hepatitis B; Interferon; Lamivudine; Treatment

Indexed keywords

ALPHA2 INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADOLESCENT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FEVER; HEPATITIS B; HUMAN; HYPOTHYROIDISM; LEUKOPENIA; LONG TERM CARE; MALE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; AGE FACTORS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INFANT; INTERFERON-ALPHA; LAMIVUDINE; MALE; TREATMENT OUTCOME;

EID: 33846073127     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000243439.47334.4e     Document Type: Article

References (33)

1. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
2. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5.
3. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-95.
4. Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
5. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
6. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
7. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
8. Conjeevaram HS, Di Bisceglie AM. Management of chronic viral hepatitis in children. J Pediatr Gastroenterol Nutr 1995;20:365-75.
9. Wai CT, Chu CJ, Hussain M, et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-30.
10. Bortolotti F, Jara P, Barbera C, et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000;46:715-8.
11. Vo Thi Diem H, Bourgois A, Bontems P, et al. Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr 2005;40:141-5.
12. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
13. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-63.
14. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-75.
15. Artan R. Lamivudine monotherapy in children with immune-tolerant chronic hepatitis B virus. J Chemother 2005;17:198-202.
16. Park N, Shin J, Park J, et al. Predictive factors and efficacy of lamivudine treatment in chronic hepatitis B infection. Korean JGastroenterol 2003;42:303-12.
17. Hsu HY, Chang MH, Chen DS, et al. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986;18:301-7.
18. Hsu HY, Chang MH, Lee CY, et al. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. Hepatology 1992;15:382-6.
19. Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-45.
20. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80.
21. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41.
22. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-7.
23. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
24. Marrone A, Zampino R, Portella G, et al. Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B. J Viral Hepat 2005;12:186-91.
25. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
26. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22.
27. Hong S, Han K, Ahn S, et al. Long-term efficacy and durability of lamivudine therapy in patients with chronic hepatitis B. Korean J Hepatol 2001;7:423-31.
28. Dikici B, Ozgenc F, Kalayci AG, et al. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study. J Gastroenterol Hepatol 2004;19:127-33.
29. Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, et al. Effi-cacy of lamivudine in the treatment of children with chronic hepatitis B. Hepatol Res 2005;31:217-22.
30. Hom X, Little NR, Gardner SD, et al. Predictors of virologic response to lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J 2004;23:441-5.
31. Dikici B, Ece A, Bosnak M. Which combination should be preferred in the management of children with chronic hepatitis B infection? J Clin Gastroenterol 2005;39:745-6.
32. Ozgenc F, Dikici B, Targan S, et al. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection. Antivir Ther 2004;9:23-6.
33. Saltik-Temizel IN, Kocak N, Demir H. Lamivudine and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection. J Clin Gastroenterol 2005;39:68-70.